Beckley Psytech has announced a new clinical trial investigating its novel formulation of the psychedelic drug DMT for the treatment of depression.
The therapeutic benefits of many psychedelics have been clearly demonstrated through clinical trials, where the use of psilocybin-, ketamine-, and MDMA-assisted psychotherapy showed striking long-term improvements...
In a new brain-imaging study, UK researchers will explore how DMT impacts brain function, behaviour and well-being.
Researchers at Johns Hopkins Medicine have found that just a single psychedelic experience may increase a range of beliefs about consciousness, meaning and purpose.
Awakn Life Sciences has announced that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe alcohol use disorder (AUD)...
Germany’s Federal Ministry of Education and Research (BMBF) has provided a grant of €2.6m for a study exploring the efficacy of psilocybin as a treatment for...
Data from Diamond Therapeutics’ trial is the first to identify a safe, active and non-psychedelic dosage of psilocybin, which the company says could open the possibility...
COMPASS Pathways has presented new, positive data demonstrating the potential of COMP360 psilocybin therapy in depression at the Annual Meeting of the American College of Neuropsychopharmacology...
A team of researchers at the University of Pennsylvania School of Medicine have published findings which show how ketamine dramatically reorganises activity in the brain –...
An increasing amount of research is investigating the efficacy of psychedelic mushrooms for the treatment of a number of health conditions, however, knowledge about how psychedelic...